Table 2.
Baseline data of tacrolimus-receiving patients.
| Time after Transplantation | 1–5 Years (Tacro + MMF) |
>5 Years (Tacro + MMF) |
1–5 Years (Tacro) |
>5 Years (Tacro) |
ANOVA |
|---|---|---|---|---|---|
| Age ± SD (years) (range) |
51.70 ± 13.48 (19–75) |
55.04 ± 10.57 (29–73) |
52.42 ± 12.83 (34–75) |
56.01 ± 10.89 (26–71) |
p = 0.873 |
| Tacro dose ± SD (mg) (range) |
5.03 ± 2.47 (1.5–13) |
4.58 ± 2.06 (2–9) |
5.70 ± 2.83 (2–10) |
5.44 ± 2.68 (1–10) |
p = 0.430 |
| Therapeutic range of the AUC(0–12) exposure (µg/h/L) |
120–150 | 120–150 | 120–150 | 120–150 | - |
| AUC(0–12) ± SD (µg/h/L) (range) |
146.97 ± 53.04 (68–379) |
129.73 ± 36.70 (59–235) |
113.90 ± 17.95 (77–138) |
129.72 ± 38.09 (50–195) |
p = 0.055 |
| Therapeutic range of the C0 concentration (µg/L) | 4–6 | 3–5 | 4–6 | 3–5 | - |
| C0 ± SD (µg/L) (range) |
8.23 ± 2.81 (4.05–18.58) |
7.23 ± 2.14 (3.13–13.63) |
6.12 ± 1.47 (4.02–9.66) |
7.54 ± 2.67 (3.26–13.81) |
p = 0.022 |
| Number of subjects | 72 | 44 | 10 | 18 | 144 |
ANOVA—analysis of variance; CsA—cyclosporine; MMF—mycophenolate mofetil; Tacro—tacrolimus; SD—standard deviation.